Prognostic Role of Ki-67 Labeling Index in Neuroendocrine Tumors of Heterogeneous Origin: Experience in a Single Center

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 327-337-Neuroendocrine Tumors
Clinical
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-329
Antonio Bianchi*1, Donato Iacovazzo1, Francesca Lugli1, Francesca Plastino1, Giovanni Schinzari1, Giorgio Treglia1, Maria Vittoria Rufini1, Frediano Inzani1, Alberto Larghi1, Maria Gabriella Brizi1, Pierluigi Granone1, Domenico D'Ugo1, Giovanni Battista Doglietto1, Carlo Antonio Mario Barone1, Guido Rindi1, Alfredo Pontecorvi2 and Laura De Marinis2
1Catholic University, Rome, Italy, 2Catholic University School of Medicine, Rome, Italy
Many studies concerning prognostic factors in NETs have been done, but there are no data about patients with NETs of heterogeneous origin. The aim of our study was to evaluate the prognostic factors for NETs in a center with integrated multidisciplinary approach to these tumors.

We report the results of a retrospective and prospective study regarding 54 patients (27 M, 27 F, median age 60 years) affected by neuroendocrine tumor, that came to our observation consecutively between 2005 and 2009. Twenty-six were affected by GEP-NETs, 27 by lung NETs and 2 patients presented with metastases from occult primary tumor. Treatment options and response to treatment have been evaluated according to the new classification of NETs (WHO 2010), that provides a grading system based on Ki-67 labeling index and mytotic count. The study population, according to this classification, has been divided into three distinct categories: G1 (38 patients), G2 (14 patients) and G3 (2 patients). Our results showed that the tumor grading is the most significant predictor of outcome. The survival curve showed a clear distinction in terms of disease-free interval between the three classes of grading, although statistical significance was not reached between G2 and G3, probably because of the paucity of G3 cases.

Our results confirm that the approach to these tumors should be multidisciplinary and show, for the first time in an heterogeneous series, that an accurate histopathological evaluation including tumor grading is crucial for a proper and effective therapeutic choice.

Nothing to Disclose: AB, DI, FL, FP, GS, GT, MVR, FI, AL, MGB, PG, DD, GBD, CAMB, GR, AP, LD

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm